Neviah Genomics

Neviah Genomics focuses on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Neviah Genomics will aim to satisfy the growing market need for products to predict toxicity profiles of drug candidates at an early stage of development, thereby minimizing attrition and mitigating risk of late-stage drug failure. Neviah Genomics operates out of the Israel Bioincubator in Yavne, Israel.

Team Member
more about
Jasper Bos
all portfolio news